Deliberations of the Combined General Meeting of June 15, 2022


> All resolutions passed in accordance with the recommendations of the Board of Directors

> Mr. Khalil Barrage, Managing Director of Invus’ Public Investments Unit, appointed new member of the Board of Directors

PARIS, June 16, 2022–(BUSINESS WIRE)–Regulatory news:

Onxeo SA (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), (“Onxeo“or the”Company“), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA damage response (DDR), in particular against rare or resistant cancers, announces that the Combined General Meeting held this day adopted all the resolutions presented, in accordance with the Recommendations of the Board of Directors.

Furthermore, the shareholders of the Company approved the appointment of Mr. Khalil Barrage as a new director for a term of 3 years. Mr. Barrage is a managing director at Invus, based in New York. He joined Invus in 2003 and created his Public Equity activity. Since its inception, Invus Public Equity has focused its investments in emerging innovative biotechnology companies. Prior to joining Invus, he worked at The Olayan Group in New York and managed their US equity portfolio for 15 years. He holds a BA in Economics from the American University of Beirut. He is a board member of several biotechs including Celtaxsys and Protagenic Therapeutics in the United States and Sensorion in France. The shareholders also approved the renewal of the directorship of GammaX Corporate Advisory, represented by Mr. Jacques Mallet, for an additional period of 3 years.

Onxeo’s Board of Directors, chaired by Ms. Shefali Agarwal, thus has 8 members, 5 of whom are independent.

Dr. Shefali Agarwal, Chief Executive Officer of Onxeo, commented : “On behalf of the entire Onxeo team, I would like to thank all our shareholders for their commitment and support during this General Meeting. I am delighted to welcome Mr. Khalil Barrage to our Board of Directors. Mr. Barrage brings a wealth of experience and allows us to strengthen our ties with our main shareholder, a global fund very committed to the field of biotechnology and committed to supporting innovative companies like ours in the next stages of our growth. I would also like to congratulate Jacques Mallet, whose mandate has been renewed and who, in recent months, has made a considerable contribution to the Board and to the company“.

The results of the votes and the minutes of the General Meeting of Shareholders will be available within the legal deadline on the Company’s website, at the address General Meetings section.

Next financial communication:

About Onxeo

Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after area of ​​tumor damage response. DNA (DDR). The Company is focused on bringing novel or innovative compounds from early-stage translational research to clinical proof of concept, an attractive value-creating inflection point for potential partners.

Plato is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and expands the Company’s product portfolio.

AsiDNA, platON’s first compound, is a highly differentiated clinical-stage first-in-call candidate in the field of DNA damage response (DDR) applied to oncology. Its decoy and agonist mechanism acting upstream of several DDR pathways results in distinctive antitumor properties, including the ability to prevent or abrogate tumor resistance to targeted therapies such as PARP inhibitors and strong synergy with tumor-damaging agents. tumor DNA such as radio-chemotherapy. AsiDNA is currently undergoing combined clinical trials in hard-to-treat solid tumors.

OX401 is a new drug candidate from platON, designed to be a next-generation PARP inhibitor acting both on the DNA damage response and on the activation of the immune response, without inducing resistance. OX401 is currently being optimized and undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.

For more information, please visit

Forward-looking statements

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. These statements involve certain known and unknown risks, uncertainties and other factors, which could cause Onxeo’s actual results, financial condition, performance or achievements to be materially different from any future results, performance or achievements expressed or implied. implied by these forward-looking statements. . Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of the risks and uncertainties that could cause Onxeo’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the risk factors described in the most recent reference of the Company or in any other periodic financial report and in any other press release, which are available free of charge on the Company’s Group websites ( and/or the AMF (

See the source version on


Valerie Leroy,
Investor Relations
[email protected]
+33 1 45 58 76 00

Media Relations
Arthur Rusty
[email protected]
+33 1 44 71 94 98

Investor Relations / Strategic Communication
Dušan Orešanský / Emmanuel Huynh
[email protected]
+33 1 44 71 94 92

Certified Advisor for Nasdaq First North
capital partner
[email protected]
+45 89 88 78 46


About Author

Comments are closed.